A Agilent Technologies Inc.

Agilent Announces High-Performance Cary 3500 Flexible UV-Vis System

(NYSE: A) today announced the latest addition to the Cary 3500 UV-Vis Series with the release of the . This new solution is a double-beam spectrophotometer with advanced photometric performance for diverse sample-type measurements with minimal sample preparation. The Cary 3500 UV-Vis Series can be deployed in regulated environments, specifically the pharma/biopharma industry.

The new Cary 3500 Flexible UV-Vis system offers a uniquely large sample compartment with a small footprint for analyzing a range of liquid samples and characterizing solid samples. The full Cary 3500 UV-Vis spectrophotometer series also includes a 10-year warranty xenon flash lamp, (for Cary 3500 instruments purchased from Agilent or participating partners), drastically reducing the frequency and cost of deuterium lamp replacement, and eliminating the daily warmup time.

Another key development is the enhancement of the . New calculations can now be saved and applied automatically to any method routinely used to reduce data processing time and calculation errors. It is accessible to new customers and existing users who want to upgrade to the latest software version. Additionally, the Cary 3500 UV-Vis spectrophotometer series, including the new UV-Vis Flexible module, can be deployed with the to help organizations achieve their data management and compliance goals.

“The Cary 3500 Flexible UV-Vis spectrophotometer is the next major step in a long history of UV-Vis innovation at Agilent,” said Geoff Winkett, vice president and general manager of Agilent’s Molecular Spectroscopy Division.

Winkett continued. “The series has been an incredible success since its introduction in 2018 and our customers—particularly those in the pharma and biopharma industries—have benefitted from the unique range of capabilities. This further strengthens our distinctive portfolio of integrated solutions under the Agilent OpenLab umbrella, from chromatography to mass spectroscopy, to UV-Vis spectroscopy.”

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, please subscribe to the Agilent . Follow Agilent on and .

EN
03/04/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Agilent Technologies, Inc.: Key facts and statistics - fiscal 2025

A summary company profile, detailing Agilent Technologies, Inc.’s business operations and financial highlights.

Agilent Technologies, Inc. - October 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Agilent Technologies, Inc.: Update to credit analysis

Our credit view of this issuer reflects its low financial leverage, against its high proportion of revenue from costly equipment sales, which has exposure to cyclical demand fluctuations

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Agilent Technologies, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 11 December 2025 in which we reassessed the appropriateness of the ratings in th...

Agilent Technologies Inc: 1 director

A director at Agilent Technologies Inc sold 2,600 shares at 149.812USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch